Form 4: Pyxis Oncology CEO Lara Sullivan Acquires 1,135,000 Stock Options
SEC Filing Form 4
Lara Sullivan, CEO of Pyxis Oncology, acquired 1,135,000 stock options on December 23, 2024, vesting fully on December 23, 2025, subject to continued employment.
Summary
- Lara Sullivan, the CEO of Pyxis Oncology, filed a Form 4 on December 23, 2024.
- The filing reports the acquisition of 1,135,000 stock options with an exercise price of $1.67.
- These options vest fully on December 23, 2025, contingent upon Sullivan's continued employment with the company.
- The options expire on December 23, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by the CEO suggests confidence in the company's future performance and aligns her interests with shareholders.
Positives
- The acquisition of stock options by the CEO could align her interests with those of the shareholders, incentivizing her to improve the company's performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- Shareholders may view the CEO's acquisition of stock options positively, as it aligns her interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 12/23/2024 | Date of the transaction and filing of Form 4; Lara Sullivan acquired 1,135,000 stock options. |
| 12/23/2025 | Vesting date for the stock options, contingent upon continued employment. |
| 12/23/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.